Lindsey Link
Medical · Coalport, PANPI 1487107330
Payments from drug & device makers
Across 214 payments — averaging $15.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$583
- Novo Nordisk$533
- Pfizer$358
- Lilly USA, LLC$342
- Amgen$321
- Amarin Pharma, Inc.$228
- plus $996 from 20 others
What the payments were for
- Food & beverage$3,361100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 42 | $583 |
| Novo Nordisk | 37 | $533 |
| Pfizer | 23 | $358 |
| Lilly USA, LLC | 21 | $342 |
| Amgen | 19 | $321 |
| Amarin Pharma, Inc. | 14 | $228 |
| Biohaven Pharmaceuticals, Inc. | 7 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $122 |
| GSK | 5 | $78 |
| Astellas Pharma US Inc | 4 | $75 |
| Merck | 4 | $70 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $66 |
| AstraZeneca | 4 | $61 |
| Johnson & Johnson | 3 | $60 |
| Boston Scientific | 2 | $55 |
| Exact Sciences | 3 | $47 |
| Sanofi | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Gilead | 2 | $35 |
| Sanofi Pasteur Inc. | 2 | $27 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Ardelyx, Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Hologic Sales And Service, LLC | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
How this compares
$3,361 in reported general payments places this provider in the 85th percentile of 2,594 medical providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 92 | $106,372 |
| JardianceEmpagliflozin | 66 | $51,409 |
| EliquisApixaban | 39 | $28,120 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $25,477 |
| MounjaroTirzepatide | 24 | $25,240 |
| XareltoRivaroxaban | 19 | $19,538 |
| TradjentaLinagliptin | 15 | $17,771 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $14,792 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $11,961 |
| MyrbetriqMirabegron | 12 | $6,453 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,392 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $5,233 |
| VascepaIcosapent Ethyl | 13 | $4,471 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,150 |
| Rosuvastatin Calcium | 186 | $2,955 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $533 | $106,37292 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $78 | $46,97980 claims |
| PfizerEliquis | $358 | $28,12039 claims |
| Lilly USA, LLCMounjaro | $342 | $25,24024 claims |
| Johnson & JohnsonXarelto | $60 | $19,53819 claims |
| Astellas Pharma US IncMyrbetriq | $75 | $6,45312 claims |
| AbbVieSynthroid | $583 | $80828 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,594 medical providers in Pennsylvania.
Other medical in Coalport
- Jacqueline KernaghanSpringfield$427K
- Drew SodaNew Hope$220K
- Angela KapalkoPhiladelphia$123K
- Linda PerryPhiladelphia$123K
- Cory DavidsonErie$119K
- Shelley SassamanTamaqua$90K
- Meghan HoffnerBethlehem$86K
- Thomas IacovoniDanville$72K
- Scott CoxWynnewood$66K
- Sarah SmithPhiladelphia$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.